INTRODUCTION
Hemophilia A is a congenital bleeding disorder caused by a deficiency of coagulation factor VIII (FVIII). Currently hemophilia patients are treated with repeated infusions of plasma-derived or recombinant FVIII protein concentrates. Gene therapy is expected to provide a more beneficial and cost effective treatment for this disease. We have demonstrated previously that naked DNA transfer of a liver-specific, high-expressing plasmid (pBS-HCRHPI-hFVIIIA) into Rag2(-/-) severe combined immune deficient (SCID) mice led to persistent high-level expression of human factor VIII (hFVIII) 1 . Supra-physiologic expression levels of hFVIII were also achieved in immunocompetent hemophilia A mice, leading to complete but transient phenotypic correction
during the first few days post gene therapy treatment. However a strong humoral immune response against hFVIII subsequently completely inhibited circulating hFVIII activity in immunocompetent hemophilia A mice 2 .
The formation of inhibitory antibodies to infused hFVIII represents a major complication in the clinical treatment of hemophilia A patients. A similar problem is predicted to occur following gene therapy for hemophilia A. Various strategies have been explored to modulate the immune responses in hFVIII-treated hemophilia patients and in hemophilia A murine models undergoing repetitive hFVIII protein delivery. High dose tolerance induction protocols are very expensive and only partially effective 3, 4 . Anti-CD40L 5 , cyclosporine A 6 , and Rituximab 7, 8 , have each been successfully used to treat acquired Hemophilia A in individuals who developed anti-FVIII autoantibodies. A partial suppressive response has been achieved in a group of hemophilia A patients using a combination of high dose hFVIII tolerance induction, and cyclophosphamide, with or without concomitant IVIG therapy 9, 10 . Notably, both the immune response to hFVIII and the effectiveness of immunomodulation appear to differ significantly in patients with congenital only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From and those with acquired hemophilia A, with more frequent responses and better results in the acquired cases. This difference is likely related, at least in part, to the sustained presence of circulating hFVIII antigen in the latter group of patients. In hemophilia A mice, acquisition of inhibitors requires expression of the B7 co-stimulating molecule because treatment with Ctla4-Ig transiently blocks the response to repeated hFVIII protein infusion 11 . Treatment with anti-CD40L
to disrupt signaling via CD40 also delays anti-hFVIII antibody formation in this model 12, 13 .
However, long term tolerance has not been achieved in any of these animal models 12, 13 . Recently several new strategies to prevent the production of inhibitory antibodies have also been reported, including high doses of FVIII to inhibit FVIII-specific memory B cells 14 , oral feeding of FVIII-C2 domain 15 , lipopolysaccharide (LPS)-activated B-cell blasts transduced with a fusion IgG containing the C2 or A2 domains of FVIII 16 , and ex vivo transduction of hematopoietic stem cells 17 .
In the hFVIII gene transfer mouse model using naked DNA of a liver-specific, high-expressing hFVIII plasmid previously established in our laboratory 2 , the expression of hFVIII leads to a predominantly Th2 immune response associated with high-titer anti-hFVIII antibodies that persist for the life of the animals. In this report, we have evaluated and compared multiple candidate immune suppression strategies designed to modulate or prevent the generation of hFVIII-specific T and B cells and the production of high affinity inhibitory antibodies of the IgG isotype. To accomplish this, we designed protocols to eliminate or reduce key effector populations (antigenspecific B and CD4+ T cells), modulate T-helper cell activation, alter T/B cell interactions, or inhibit specific pathways of T and /or B lymphocyte activation. Immuno-modulation strategies were designed to meet the following criteria: (1) only transient exposure to immunosuppression;
(2) inhibition of one or more critical B and/or T cell activation pathways; (3) induction of minimal only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From cytoablation and other associated toxicity; and (4) minimal effects on immune competence. These experimental criteria are essential for the translation of such protocols into human gene therapy trials. We demonstrate that suppression of immune responses against FVIII is most effectively achieved by combined immunomodulation therapy at the time of hFVIII plasmid transfer using a combination of murine Ctla4-Ig and anti-murine CD40L (MR1), and most importantly, that transient inhibition of co-stimulatory molecules can promote long-term immune tolerance that is specific for hFVIII allowing long-term gene correction in immunocompetent hemophilia A mice.
only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From
MATERIALS AND METHODS

Construction of Vectors.
The construction of pBS-HCRHPI-hFVIIIA containing a B-domain deleted human factor VIII cDNA 18 has been described previously 1 .
Animal Experiments. Animals were kept according to the National Institutes of Health guidelines for animal care and the guidelines of the Children's Hospital and Regional Medical Center, Seattle. Hemophilia A mice in 129/SV x C57BL/6 mixed genetic background were prepared by Following plasmid injection, mice selected for transient immunosuppression received the immunomodulation components intraperitoneally according to the dosage and schedule listed in Table 1 . Combination therapy was given using the same schedule and dosages as the single agent.
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Serially diluted normal human plasma was used as standard. hFVIII activity was quantitated by a chromogenic assay (COATEST, measuring factor Xa generation; Chromogenix AB, Sweden), and a modified clotting assay utilizing activated partial thromboplastin time (APTT) reagent and factor VIII deficient plasma. hFVIII levels were calculated from a standard curve generated by using a series of dilutions of normal human pooled plasma.
Assays for anti-hFVIII antibodies and their subclasses. Inhibitory antibodies were measured by
hFVIII Bethesda assays as previously described 23 . Total antibodies against hFVIII were detected by an antigen-specific ELISA technique using a plasma derived, monoclonal antibody-purified commercial factor VIII protein concentrate (Monarc-M, American Red Cross, prepared by Baxter Healthcare Corporation, Glendale, CA) and horseradish peroxidase-conjugated monoclonal antibodies against total murine IgG as described 1 .
Evaluation of hFVII-specific IgG subclasses. Antigen-specific IgG subclasses were evaluated by ELISA using hFVIII coated plates and horseradish peroxidase-conjugated antibodies for different The background levels of hFVIII-specific IgG subclasses measured in untreated hemophilia A mice were negligible (<10ng/ml).
Cytokine production and proliferation assay by stimulated spleen cells. Spleens were removed aseptically from hemophilia A mice 180 days post plasmid and Ctla4-Ig and MR1 treatment, and single cell suspensions prepared in RPMI 1640 medium (Invitrogen) containing 2mM glutamine, 50µM 2-mercaptoethanol (2-ME), 100U/ml penicillin, 100 µg/ml streptomycin, and 10% fetal calf serum. Naïve hemophilia A mice were used as controls. Red blood cells were lysed with sterile 17mM Tris and 140mM NH 4 Cl buffer, pH 7.4. For cytokine production assays, isolated spleen cells (1 x 10 5 cells/200µl/well) were stimulated on day 0 with 10µg/ml Phytohemagglutinin (PHA) or 20U/ml hFVIII protein (Monarc-M which had been extensively dialyzed against 50mM
Imidazole buffer as described above) or 4µg albumin in imidazole buffer as control. Culture supernatants were collected over a six day period and stored at -80 o C. IL-2, interferon-γ and IL-10 were determined by ELISA using specific antibodies and standards purchased from BD Pharmingen (San Diego, CA). For assessment of proliferation, triplicates of isolated spleen cells
(1 (Fig. 1C) , concomitant with the appearance of antibody formation (Fig. 1D ). This pattern is indistinguishable from that observed in plasmid-treated mice without immunomodulation (Fig. 1A & B) . Mice treated with RAP had a slightly delayed immune response with inhibitory antibodies appearing at 3-4 weeks post plasmid delivery. Eventually, however, the hFVIII concentrations dropped to undetectable levels with the appearance of high-titer inhibitory antibodies as shown in Fig. 1E&F . Among the three single agent regimens, MMF was most effective in suppressing the immune responses against hFVIII.
Two of the four mice treated with MMF had a significantly delayed immune response with hightiter antibody appearing 4-8 weeks post plasmid delivery when hFVIII levels dropped to undetectable levels (Fig. 1G&H) . The other two mice developed very low-titer inhibitory only.
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Antigen specific IgG subclasses following single immunosuppressive agent therapy. It has been shown previously that the majority of anti-hFVIII IgG in this model is of the IgG1 isotype, however small amounts of anti-hFVIII antibodies of the IgG2a, IgG2b, and IgG3 isotype were also detected. These findings suggest that transgene-specific antibodies are predominantly generated in response to Th2 induced activation signals.
To further characterize the nature of the immunosuppressive effect, we examined the antihFVIII IgG subclass specificity using an ELISA based assay in plasmid-treated mice receiving single-agent immunomodulation therapy (Fig. 2) . Treatment with CSA did not significantly alter the production of any antigen-specific IgG isotype except for a slight reduction of the IgG3 isotype antibodies. RAP treatment considerably reduced the production of IgG2b and IgG3 but not IgG1 and IgG2a isotypes. The two MMF treated animals that exhibited long-term hFVIII expression and low-titer inhibitory antibodies did not generate detectable levels of inhibitors of any IgG isotype. The other two MMF treated animals which produced high-titer inhibitors had a reduction in IgG1 and IgG2b but not in IgG2a and IgG3 antigen-specific isotypes.
Combination immunosuppressive therapy with CSA/MMF or RAP/MMF. To further suppress the inhibitory antibody response to hFVIII, we explored the effects of combining two immunosuppressive agents, e.g., CSA plus MMF, and RAP plus MMF, respectively. While delayed and reduced immune responses were observed in either of the combination therapy, hightiter inhibitory antibodies eventually developed and eliminated functional hFVIII levels in all treated animals (Fig.1I, J, K & L) . Surprisingly, the combination therapies appeared to be less only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From effective than MMF alone. It is unclear whether these differences reflect heterogeneity in the humoral immune response to hFVIII as has been observed by others, or another mechanism that reduces the efficacy 12, [25] [26] [27] . Because the hemophilia A mice used in these studies are of mixed genetic background (129sv x C57BL/6), the resulting heterogeneity may have contributed to this variability.
Immunomodulation therapy with Ctla4-Ig, anti-CD40L mAb (MR1) or a combination of both
agents. Three groups of plasmid pBS-HCRHPI-hFVIIIA treated mice were evaluated ( For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From demonstrating that transient immunomodulation given at the time of gene transfer can induce long-term tolerance following gene therapy. In addition, the expression levels of FVIII and inhibitor titers were followed in three tolerized mice for up to one year; no significant changes were observed compared to those obtained at 5 months post treatment.
Antigen specific IgG subclasses following combination immunomodulation therapy. We similarly evaluated the anti-hFVIII IgG subclasses in the plasmid-treated mice exposed to Ctla4-Ig and/or anti-CD40L mAb (MR1) (Fig. 4) . Treatment with Ctla4-Ig alone slightly reduced the production of IgG2b, and more significantly IgG3, but did not alter significantly the production of IgG1 and IgG2a isotypes. MR1 treatment considerably reduced production of IgG2a, IgG2b, and IgG3, and moderately reduced the production of IgG1. As expected, mice treated with the combination of Ctla4-Ig and MR1 had undetectable levels of all four IgG isotypes, suggesting a synergistic interaction between these two agents. For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From 10 secretion in response to hFVIII was significantly higher in plasmid-treated hemophilia A mice compared with untreated mice, whereas IL2 and IFN-γ production was only slightly increased.
These findings are consistent with a Th2 dominant immune response to hFVIII in this model.
These results are comparable to those seen in animals that were challenged with hFVIII protein 28 .
Most importantly, mice tolerized by the combination therapy with Ctla4-Ig and MR1 showed neither an increase in cytokine production nor enhanced T cell proliferation when stimulated with hFVIII.
Long-term immune tolerance is specific for hFVIII. To evaluate whether short-term immunomodulation led to long-term defects in host immune function, animals were challenged six months post plasmid injection with the T dependent neoantigen, bacteriophage Φx174 29 .
Three groups of mice (n=2/group) were immunized twice, four weeks apart, including The majority of anti-hFVIII antibody in the plasmid-treated mice is of the IgG1 isotype, but IgG2a, IgG2b, and IgG3 antibodies are also present. These findings suggest that the immune response in these animals is mediated mainly by Th2-induced signals. Most notably, by using "naked gene transfer", it is unlikely that these immune responses are driven or potentiated by viral vector components as we observe little decline in plasmid containing hepatocytes over time. This model therefore represents an excellent system to study inhibitory antibody formation generated via persistent transgene expression, and permits us to investigate potential immunomodulation strategies designed to prevent or eliminate the formation of inhibitory antibodies against hFVIII.
In established animal models of tolerance, the presence of antigen appears to be required to We used the model of long-term expression of hFVIII following naked plasmid delivery to explore the effect of combining the administration of plasmid DNA with transient immunosuppression to induce long-term tolerance in hemophilia A mice. As has been shown previously 2 , the administration of the cytotoxic and immunosuppressive agent cyclophosphamide following pBS-HCRHPI-hFVIIIA injection resulted in the prevention (1/6 animals) or delay (5/6 animals) of inhibitory antibody formation against the transgene. The complete and sustained phenotypic correction of hemophilia A achieved in one animal following transient immunomodulation with cyclophosphamide lasted for greater than 6 months, strongly suggesting that consistent tolerance to this "neoantigen" and adequate expression of functional hFVIII might be achievable with an optimized immunosuppressive regimen.
We therefore evaluated multiple immunosuppressive strategies (Table 2) designed to prevent and/or modulate the generation of hFVIII-specific T-cells and the production of inhibitory antibodies by hFVIII specific B cells without induction of nonspecific tolerance. We first evaluated single agents that target the signaling events essential for sustained T cell activation.
Cyclosporine A (CSA) inhibits proximal T-cell receptor (TCR) dependent signals, thereby suppressing the early stages of lymphocyte activation. This agent is used routinely in a broad range of applications including humans with acquired hFVIII inhibitory antibodies. The bacterial macrolide, rapamycin (RAP), is a potent immunosuppressant and a promising anti-cancer drug. In only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From forming a complex with its cellular receptor, the FK506-binding protein (FKBP12), RAP binds and inhibits the function of the mammalian target of rapamycin (mTOR). RAP inhibits T cell proliferation following mitogen (PHA) and/or alloantigen (MLR) stimulation. Currently, no published experience with RAP exists in human hemophilia or related animal models.
Mycophenolate mofetil (MMF) as well as cyclophosphamide were used for nonspecific inhibition of B and T cell proliferation and the production of antibodies. MMF is approved for the prevention of renal transplant rejection and is used to treat a wide range of autoimmune disorders.
Our results demonstrate that neither single agent nor combined therapy with any of these three agents was sufficient to prevent antibody formation against hFVIII, although treatment with MMF considerably suppressed the production of antigen-specific IgG1 and IgG2b antibodies; the effect, however, was not potent enough to prevent the induction of long-lasting inhibitory antibodies. For Based on the limited effects observed with either Ctla4-Ig or anti-CD40L alone, we combined these two agents to simultaneously target both effector pathways to induce tolerance. As shown in Interestingly neither Ctla4-Ig nor anti-CD40L treatment alone achieved a significant inhibitory effect whereas the combined therapy induced long-term tolerance. This strongly suggests that the two compounds act synergistically in blocking distinct activation pathways.
Furthermore T cells from tolerized mice remained non-responsive to hFVIII exposure in vitro only.
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In our experiments, Ctla4-Ig was less effective than MR1 when used alone in reducing the titer of anti-hFVIII antibodies. This result is different from those obtained from immuno-modulation of adenoviral gene transfer of factor IX where Ctla4Ig was more effective than MR1 36,37 . In the latter case, the inhibitory response was primarily induced against viral vectors to generate predominantly cytotoxic lymphocyte (CTL) that led to destruction of transduced cells. Therefore, blocking CD28 pathway is likely more effective to block T-cell dependent responses whereas the blocking of antibody production through CD40L pathway is less effective. In contrast, in the plasmid-treated hemophilia A mice, the inhibitory response is predominantly a humoral response against the transgene product, hFVIII, and MR1 which blocks T help function is apparently more effective than Ctla4Ig alone for blockade of the antibody response. CD40L also enhances APC function by inducing expression of the B7 proteins. Thus, the synergistic effect of dual blockade of both CD28 and CD40L co-stimulatory pathways with Ctla4-Ig and MR1 induced long-term antigen-specific tolerance but not a general immunodeficiency, fulfilling the requirements listed in the introduction section.
A clinical trial to induce tolerance is a logical next step to test the efficacy of combined immunomodulation therapy using CTLA4-Ig and anti-CD40L in humans. CTLA4-Ig does not seem to induce permanent immune compromise in humans 44 and has recently been approved by the FDA for clinical use. Clinical trials to test efficacy and safety of anti-CD40L have yielded controversial results. In particular, some trials induced thrombotic events or increased thrombotic risks in patients 45, 46 , whereas some did not 47 . In another study 48 , administration of heparin in conjunction with anti-CD40L also reduced the frequency of thromboembolic complications. In -stimulation blockade) . hFVIII levels and inhibitory antibody formation over time in hemophilia A mice after treatment with pBS-HCRHPI-hFVIIIA beginning on day 1. Transient immunomodulation included: Ctla4-Ig on days 1 and 2 (n=8 total; A,B); MR1 on days -1, 1, 2, 7 and 14 (n=9 total; C,D); and Ctla4-Ig with MR1 (n=9 total; E,F) using the same combined schedule and dosages as with each individual agent. Fifty μg of the plasmid in 2ml saline solution was injected into the tail vein of mice in 5-8 seconds. Two separate cohorts of animals (n=4-5/group) were used at separate times for each set of immunomodulation experiments; the data from two cohorts were combined and presented in the figure. Respective immunosuppressive drugs were administered intraperitoneally at indicated times. # denotes the death of one treated mouse in (C). Mice were bled at regular intervals. Circulating hFVIII activities and inhibitory antibody titers were evaluated as in Fig 1.   Figure 4 . Subclasses of anti-hFVIII IgG immunoglobulin in hemophilia A mice after naked plasmid transfer of pBS-HCRHPI-hFVIIIA with or without immunomodulation (costimulation blockade). Titers of subclasses of IgG including IgG1, IgG2a, IgG2b, and IgG3 produced at two months following gene transfer were determined by IgG subclass-specific ELISA. All animals treated as described in Figure 3 were tested and their levels were averaged except that in the MMF-treated group, the IgG levels from only 3 mice that developed inhibitors were averaged. Figure 5 . Proliferation assay following in vitro stimulation of T cells isolated from hemophilia A mice. Two animals per group were untreated (n=2, -Δ-), hFVIII plasmid-treated (n=2, -o-), or hFVIII plasmid-treated receiving immunomodulation by combination of Ctla4 and MR1 (n=2, -▲-, animals from the group shown in Fig. 3E&F ). Splenic T cells were isolated from hemophilia A mice and cultured in the presence of hFVIII for three days. T cell proliferation were measured in triplicate against a range of FVIII concentration. Each data set represents the mean Δcpm obtained from two mice. Figure 6 . Cytokine production following in vitro stimulation of T cells isolated from hemophilia A mice. Four animals per group were untreated, hFVIII plasmid-treated, or hFVIII plasmid-treated with immunomodulation by combination of Ctla4 and MR1 (4 animals from the group shown in Fig. 3E&F ). Splenic T cells were isolated from hemophilia A mice and incubated with hFVIII for six days. Production of IL-2, interferon-γ (INF-γ) and IL-10 were measured from the culture media using ELISAs. , -o-) , and untreated hemophilia A mice (n=2, -Δ-) were used as controls. Phage-neutralizing antibody activity was expressed as the rate of phage inactivation (Kv) using a standard formula 24 . Mice not receiving bacteriophage did not produce neutralizing antibody (data not shown). 
